NCT04655365View on ClinicalTrials.gov

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide capsule

160 mg po id

Trial Locations (4)

H2X 0A9

CHUM, Montreal

H3H 2R9,

CUSM, Montreal

Unknown

CHU de Québec-Université Laval, Québec

J1J 3H5

CIUSSS de l'Estrie - CHUS, Sherbrooke

All Listed Sponsors
collaborator

Astellas Pharma Europe Ltd.

INDUSTRY

lead

CHU de Quebec-Universite Laval

OTHER